Wedel Johannes, Jansen Patrick A M, Botman Peter N M, Rutjes Floris P J T, Schalkwijk Joost, Hillebrands Jan-Luuk
1 Pathology Section, Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.2 Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.3 Chiralix B.V., Nijmegen, The Netherlands.4 Institute for Molecules and Materials, Radboud University Nijmegen, Nijmegen, The Netherlands.
Transplantation. 2016 Aug;100(8):1656-66. doi: 10.1097/TP.0000000000001169.
Development of transplant vasculopathy is a major cause of graft loss and mortality in solid organ transplant recipients. Previous studies in mice have indicated that vanin-1, a member of the vanin protein family with pantetheinase activity, is possibly involved in neointima formation. Here, we investigated if RR6, a recently developed vanin inhibitor, could attenuate development of transplant vasculopathy.
Abdominal allogeneic aorta transplantation from Dark Agouti to Brown Norway rats was performed. Surface neointima was quantified 2 and 4 weeks after transplantation. Systemic vanin activity was measured, and allograft leukocyte infiltration, glutathione-synthesizing capacity, matrix metalloproteinase 9 expression and neointimal smooth muscle cell (SMC) proliferation were assessed by immunohistochemistry. In vitro, the effects of RR6 on SMC proliferation (water-soluble tetrazolium-1 assay) and cytokine-induced apoptosis (flow cytometry) were investigated.
RR6 treatment significantly reduced systemic pantetheinase activity during the 4-week follow-up period. RR6 attenuated neointima formation 4 weeks after transplantation. Neointimal SMC proliferation and medial SMC matrix metalloproteinase 9 expression were not altered by RR6. However, RR6 significantly reduced neointimal macrophage influx that was accompanied by increased GCLC messenger RNA expression. In vitro, RR6 inhibited platelet-derived growth factor-induced SMC proliferation and protected SMCs from TNF-α-induced apoptosis.
Pharmacological inhibition of vanin activity attenuates development of transplant vasculopathy. This was accompanied by reduced macrophage infiltration and increased glutathione-synthesizing capacity. In vitro, RR6 reduced SMC proliferation and apoptosis that was not confirmed in vivo. Further in-depth studies are warranted to reveal the underlying mechanism(s) of RR6-induced attenuation of transplant vasculopathy in vivo.
移植血管病变的发展是实体器官移植受者移植物丢失和死亡的主要原因。先前在小鼠中的研究表明,具有泛酰巯基乙胺酶活性的泛酰巯基乙胺蛋白家族成员泛酰巯基乙胺酶1可能参与新生内膜形成。在此,我们研究了最近开发的泛酰巯基乙胺酶抑制剂RR6是否能减轻移植血管病变的发展。
进行从暗褐鼠到棕色挪威大鼠的腹部同种异体主动脉移植。在移植后2周和4周对表面新生内膜进行定量。测量全身泛酰巯基乙胺酶活性,并通过免疫组织化学评估同种异体移植物白细胞浸润、谷胱甘肽合成能力、基质金属蛋白酶9表达和新生内膜平滑肌细胞(SMC)增殖。在体外,研究RR6对SMC增殖(水溶性四氮唑-1法)和细胞因子诱导的凋亡(流式细胞术)的影响。
RR6治疗在4周随访期内显著降低了全身泛酰巯基乙胺酶活性。RR6减轻了移植后4周的新生内膜形成。RR6未改变新生内膜SMC增殖和中膜SMC基质金属蛋白酶9表达。然而,RR6显著减少了新生内膜巨噬细胞流入,同时伴有GCLC信使RNA表达增加。在体外,RR6抑制血小板衍生生长因子诱导的SMC增殖,并保护SMC免受TNF-α诱导的凋亡。
泛酰巯基乙胺酶活性的药理学抑制减轻了移植血管病变的发展。这伴随着巨噬细胞浸润减少和谷胱甘肽合成能力增加。在体外,RR6降低了SMC增殖和凋亡,但在体内未得到证实。有必要进行进一步深入研究以揭示RR6在体内减轻移植血管病变的潜在机制。